I’m the kind of person who likes to be proactive. If I can do something that helps others and helps researchers, by participating in a clinical trial, then I think that’s a positive thing to do. I’m turning my experience into a positive and by participating in the OlympiA clinical trial, I’m doing something worthwhile so that hopefully there will be treatments available for others. – Iris
OlympiA is an international study which will enrol 1500 patients in 23 countries. It is open to women and men diagnosed with HER-2 negative breast cancer provided they have an inherited BRCA1 or BRCA2 gene mutation. The OlympiA clinical study is investigating whether taking olaparib tablets twice a day for 12 months can increase the chance of remaining free from breast cancer recurrence which may result in a new standard treatment.
More information about the study is available at www.anzbctg.org. Women and men with HER-2 negative breast cancer diagnosed in the past year and who are interested in participating in the OlympiA clinical trial should speak to their cancer specialist.